Design, synthesis, and anticancer assessment of structural analogues of (E)-1-((3,4,5-trimethoxybenzylidene)amino)-4-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]quinoxaline-2-carbonitrile (6b), an imidazo[1,2-a]quinoxaline-based non-covalent EGFR inhibitor-Reference-Cited by-同舟云学术

Design, synthesis, and anticancer assessment of structural analogues of (E)-1-((3,4,5-trimethoxybenzylidene)amino)-4-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]quinoxaline-2-carbonitrile (6b), an imidazo[1,2-a]quinoxaline-based non-covalent EGFR inhibitor

Published:2024 Issue:7 Volume:15 Page:2322-2339
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Kumar Manvendra¹^ORCID,Patil Kiran T.¹,Maity Pritam¹,Chatterjee Joydeep¹,Singh Tashvinder²,Joshi Gaurav¹³^ORCID,Singh Sandeep²,Kumar Raj¹^ORCID

Affiliation:

1. Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, India

2. Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda – 151401, Punjab, India

3. Department of Pharmaceutical Science, Hemvati Nandan Bahuguna Garhwal (A Central) University, Dist. Garhwal, Srinagar 246174, Uttarakhand, India

Abstract

Two lead compounds, 5a and 5l, designed on an imidazo[1,2-a]quinoxaline template, emerged as potent EGFR inhibitors and anti-lung cancer agents.

Funder

CSIR - Indian Institute of Chemical Biology

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00237G

Reference42 articles.

1. Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer

2. Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition

3. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

4. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

5. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer